Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials

Rajeshwari Sridhara, Sumithra J Mandrekar, Lori E. Dodd

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Progression-free survival (PFS) is frequently used as the primary efficacy endpoint in the evaluation of cancer treatment that is considered for marketing approval. Missing or incomplete data problems become more acute with a PFS endpoint (compared with overall survival). In a given clinical trial, it is common to observe incomplete data due to premature treatment discontinuation, missed or flawed assessments, change of treatment, lack of follow-up, and unevaluable data. When incomplete data issues are substantial, interpretation of the data becomes tenuous. Plans to prevent, minimize, or properly analyze incomplete data are critical for generalizability of results from the clinical trial. Variability in progressive disease measurement between radiologists further contributes to data problems with a PFS endpoint. The repercussions of this on phase III clinical trials are complex and depend on several factors, including the magnitude of the variability and whether there is a systematic reader evaluation bias favoring one treatment arm particularly in open-label trials.

Original languageEnglish (US)
Pages (from-to)2613-2620
Number of pages8
JournalClinical Cancer Research
Volume19
Issue number10
DOIs
StatePublished - May 15 2013

Fingerprint

Disease-Free Survival
Randomized Controlled Trials
Clinical Trials
Phase III Clinical Trials
Therapeutics
Marketing
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. / Sridhara, Rajeshwari; Mandrekar, Sumithra J; Dodd, Lori E.

In: Clinical Cancer Research, Vol. 19, No. 10, 15.05.2013, p. 2613-2620.

Research output: Contribution to journalArticle

@article{31ed308a85164fd2bb9a94008c09722f,
title = "Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials",
abstract = "Progression-free survival (PFS) is frequently used as the primary efficacy endpoint in the evaluation of cancer treatment that is considered for marketing approval. Missing or incomplete data problems become more acute with a PFS endpoint (compared with overall survival). In a given clinical trial, it is common to observe incomplete data due to premature treatment discontinuation, missed or flawed assessments, change of treatment, lack of follow-up, and unevaluable data. When incomplete data issues are substantial, interpretation of the data becomes tenuous. Plans to prevent, minimize, or properly analyze incomplete data are critical for generalizability of results from the clinical trial. Variability in progressive disease measurement between radiologists further contributes to data problems with a PFS endpoint. The repercussions of this on phase III clinical trials are complex and depend on several factors, including the magnitude of the variability and whether there is a systematic reader evaluation bias favoring one treatment arm particularly in open-label trials.",
author = "Rajeshwari Sridhara and Mandrekar, {Sumithra J} and Dodd, {Lori E.}",
year = "2013",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-12-2938",
language = "English (US)",
volume = "19",
pages = "2613--2620",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials

AU - Sridhara, Rajeshwari

AU - Mandrekar, Sumithra J

AU - Dodd, Lori E.

PY - 2013/5/15

Y1 - 2013/5/15

N2 - Progression-free survival (PFS) is frequently used as the primary efficacy endpoint in the evaluation of cancer treatment that is considered for marketing approval. Missing or incomplete data problems become more acute with a PFS endpoint (compared with overall survival). In a given clinical trial, it is common to observe incomplete data due to premature treatment discontinuation, missed or flawed assessments, change of treatment, lack of follow-up, and unevaluable data. When incomplete data issues are substantial, interpretation of the data becomes tenuous. Plans to prevent, minimize, or properly analyze incomplete data are critical for generalizability of results from the clinical trial. Variability in progressive disease measurement between radiologists further contributes to data problems with a PFS endpoint. The repercussions of this on phase III clinical trials are complex and depend on several factors, including the magnitude of the variability and whether there is a systematic reader evaluation bias favoring one treatment arm particularly in open-label trials.

AB - Progression-free survival (PFS) is frequently used as the primary efficacy endpoint in the evaluation of cancer treatment that is considered for marketing approval. Missing or incomplete data problems become more acute with a PFS endpoint (compared with overall survival). In a given clinical trial, it is common to observe incomplete data due to premature treatment discontinuation, missed or flawed assessments, change of treatment, lack of follow-up, and unevaluable data. When incomplete data issues are substantial, interpretation of the data becomes tenuous. Plans to prevent, minimize, or properly analyze incomplete data are critical for generalizability of results from the clinical trial. Variability in progressive disease measurement between radiologists further contributes to data problems with a PFS endpoint. The repercussions of this on phase III clinical trials are complex and depend on several factors, including the magnitude of the variability and whether there is a systematic reader evaluation bias favoring one treatment arm particularly in open-label trials.

UR - http://www.scopus.com/inward/record.url?scp=84878070728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878070728&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-2938

DO - 10.1158/1078-0432.CCR-12-2938

M3 - Article

C2 - 23669421

AN - SCOPUS:84878070728

VL - 19

SP - 2613

EP - 2620

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -